Abstract
I read with interest the article by Poupart et al.1 It reports the efficacy and tolerability of first-line immunotherapy in 136 patients with neuromyelitis optica spectrum disorder (NMOSD) with antibodies (Abs) against aquaporin-4 (AQP4, AQP4-Abs) or myelin oligodendrocyte (MOG, MOG-Abs).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
